SpringWorks Therapeutics announces Phase 2b ReNeu trial data for ASCO

SpringWorks Therapeutics “announced that four abstracts from the company’s portfolio will be presented at the 2024 American Society of Clinical Oncology Annual Meeting being held May 31 to June 4, 2024. Data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation. ReNeu is the largest multicenter trial conducted to date in patients with NF1-PN, a condition in which tumors can grow aggressively along peripheral nerves and lead to pain, disfigurement and other morbidities. In the ReNeu trial, mirdametinib treatment demonstrated deep and sustained tumor volume reductions, and improvement in pain and health-related quality of life across both the adult and pediatric cohorts.”